| Name | Title | Contact Details |
|---|---|---|
Aymii Couzelis |
Chief Information Officer | Profile |
Howard County General Hospital Inc is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies. In a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. We are also an 'end-to-end' Pharmacovigilance service provider and this includes Post Marketing Surveillance activities too.
Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Axogen is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or discontinuity to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Axogen`s comprehensive portfolio of products focuses on helping patients touch, run, feel, kiss, smile and hug—some of the many things healthy peripheral nerves allow us to do.